HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER
The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 10. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KONTEATIS ZENON D [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-10, Last update posted on www.tib.eu: 2024-01-23, Last updated: 2024-01-26 |
|---|
| Patentnummer: |
EP3774805 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA006542700 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA006542700 | ||
| 003 | DE-627 | ||
| 005 | 20240126101846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA006542700 | ||
| 035 | |a (EPA)EP3774805 | ||
| 035 | |a (EPA)67439309 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a KONTEATIS ZENON D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-10, Last update posted on www.tib.eu: 2024-01-23, Last updated: 2024-01-26 | ||
| 520 | |a The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LI MINGZONG |4 aut | |
| 700 | 0 | |a LIU PENG |4 aut | |
| 700 | 0 | |a MEDEIROS MATTHEW |4 aut | |
| 700 | 0 | |a REZNIK SAMUEL K |4 aut | |
| 700 | 0 | |a SUI ZHIHUA |4 aut | |
| 700 | 0 | |a TRAVINS JEREMY M |4 aut | |
| 700 | 0 | |a POPOVICI-MULLER JANETA |4 aut | |
| 700 | 0 | |a ZHOU SHUBAO |4 aut | |
| 700 | 0 | |a MA GUANGNING |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 10. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/67439309/publication/EP3774805A1?q=EP3774805 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2024 |b 10 |c 01 |
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 01 | ||